Epiomed Therapeutics has entered into a space act agreement with NASA's Johnson Space Center to develop and commercialize a fast-acting nasal spray to fight motion sickness in Astronauts traveling in space.
Under the agreement, Epiomed will formulate the drug called intranasal scopolamine (INSCOP), which is effective when administered as a tablet or injected.
Studies conducted with a precise dosage, demonstrated the effectiveness of INSCOP in NASA spray formulation than the oral form.
NASA Johnson Space Center treatment strategy developer Lakshmi Putcha said, "NASA and Epiomed will work closely together on further development of INSCOP to optimize therapeutic efficiency for both acute and chronic treatment of motion sickness which can be used by NASA, the Department of Defense and world travelers on land, in the air and on the seas."
In a separate agreement, Epiomed is working to test the nasal spray with the Naval Aerospace Medical Research Laboratory, which previously developed a gel formulation of INSCOP, under a space act agreement with Johnson.
In addition, after the completion of development, NASA and Epiomed will collaborate on future clinical trials related to the Federal Drug Administration requirements.
